Impact | Variation of phase III transition probabilities | |
---|---|---|
I (80%) | II (70%) | |
Overall trial success probability across all clinical phases | 15.81% | 13.37% |
Cost per successful new drug | 2190 million USD | 2390 million USD |
Cost savings per successful new drug compared to DiMasi et al. (2016) | 370 million USD (−14.4%) | 170 million USD (−6.6%) |
Global cost reductions | 14.4 bn USD | 6.6 bn USD |
Induced additional global R&D investments [lower; upper bound] | 4.22 bn USD [2.12 bn;8.44 bn] | 1.94 bn USD [0.970 bn; 3.87 bn] |
Generated gain in life-years (in US) [lower; upper bound] | 3.46 mill [1.74 mill; 6.93 mill] | 1.58 mill [1.30 mill;3.17 mill] |